| 1 Vasomotor symptoms |
7 |
1657 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.99 [‐1.10, ‐0.89] |
| 1.1 Tibolone 0.625 mg/d |
1 |
158 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.05 [‐0.46, 0.36] |
| 1.2 Tibolone 1.25 mg/day |
3 |
414 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.83 [‐1.06, ‐0.60] |
| 1.3 Tibolone 2.5 mg/day |
7 |
920 |
Std. Mean Difference (Fixed, 95% CI) |
‐1.16 [‐1.30, ‐1.03] |
| 1.4 Tibolone 5 mg/day |
1 |
165 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.84 [‐1.25, ‐0.43] |
| 2 Unscheduled bleeding |
9 |
7814 |
Odds Ratio (M‐H, Random, 95% CI) |
2.79 [2.10, 3.70] |
| 2.1 Tibolone, 2.5 mg/day |
8 |
4186 |
Odds Ratio (M‐H, Random, 95% CI) |
2.58 [1.89, 3.52] |
| 2.2 Tibolone, 1.25 mg/day |
3 |
3628 |
Odds Ratio (M‐H, Random, 95% CI) |
3.63 [2.37, 5.55] |
| 3 Endometrial cancer |
9 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 Tibolone, all doses |
9 |
8504 |
Odds Ratio (M‐H, Random, 95% CI) |
2.04 [0.79, 5.24] |
| 4 Breast cancer; women without previous breast cancer |
4 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 Tibolone, all doses |
4 |
5500 |
Odds Ratio (M‐H, Random, 95% CI) |
0.52 [0.21, 1.25] |
| 5 Breast cancer; women with previous breast cancer |
2 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 Tibolone, 2.5 mg/day |
2 |
3165 |
Odds Ratio (M‐H, Random, 95% CI) |
1.50 [1.21, 1.85] |
| 6 Venous thromboembolic events (clinical evaluation) |
5 |
9176 |
Odds Ratio (M‐H, Random, 95% CI) |
0.85 [0.37, 1.97] |
| 6.1 Tibolone (all doses) |
5 |
9176 |
Odds Ratio (M‐H, Random, 95% CI) |
0.85 [0.37, 1.97] |
| 7 Cardiovascular events |
4 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 Tibolone, all doses |
4 |
8401 |
Odds Ratio (M‐H, Random, 95% CI) |
1.38 [0.84, 2.27] |
| 8 Cerebrovascular events; women's mean age over 60 years |
4 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 Tibolone (all doses) |
4 |
7930 |
Odds Ratio (M‐H, Random, 95% CI) |
1.74 [0.99, 3.04] |
| 9 Mortality from any cause |
4 |
8242 |
Odds Ratio (M‐H, Random, 95% CI) |
1.06 [0.79, 1.41] |
| 9.1 Tibolone, 2.5 mg/day |
3 |
3736 |
Odds Ratio (M‐H, Random, 95% CI) |
0.94 [0.32, 2.73] |
| 9.2 Tibolone, 1.25 mg/day |
1 |
4506 |
Odds Ratio (M‐H, Random, 95% CI) |
0.93 [0.54, 1.59] |
| 10 Insomnia |
3 |
3432 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.19 [‐0.38, ‐0.00] |
| 10.1 Tibolone, 2.5 mg/day |
3 |
3432 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.19 [‐0.38, ‐0.00] |
| 11 Vaginal dryness and painful sexual intercourse |
3 |
3348 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.66 [‐0.90, ‐0.43] |
| 11.1 Tibolone, 1.25mg/day |
1 |
62 |
Std. Mean Difference (Fixed, 95% CI) |
‐1.78 [‐2.43, ‐1.13] |
| 11.2 Tibolone, 2.5 mg/day |
3 |
3286 |
Std. Mean Difference (Fixed, 95% CI) |
‐0.49 [‐0.75, ‐0.24] |
| 12 Vaginal infections |
2 |
7639 |
Odds Ratio (M‐H, Random, 95% CI) |
2.50 [1.24, 5.06] |
| 12.1 Tibolone, 2.5 mg/day |
1 |
3133 |
Odds Ratio (M‐H, Random, 95% CI) |
1.73 [1.17, 2.55] |
| 12.2 Tibolone, 1.25 mg/day |
1 |
4506 |
Odds Ratio (M‐H, Random, 95% CI) |
3.54 [2.61, 4.81] |
| 13 Urinary tract infections |
1 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 13.1 Tibolone, 2.5 mg/day |
1 |
3133 |
Odds Ratio (M‐H, Random, 95% CI) |
0.70 [0.46, 1.06] |
| 14 Endometrial hyperplasia |
4 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 14.1 Tibolone, all doses |
4 |
4518 |
Odds Ratio (M‐H, Random, 95% CI) |
1.20 [0.23, 6.25] |
| 15 Sensitivity Analysis ‐ Vasomotor symptoms without trials with high risk of attrition bias |
4 |
|
Std. Mean Difference (Fixed, 95% CI) |
‐0.61 [‐0.73, ‐0.49] |
| 15.1 Tibolone 0.625 mg/day |
1 |
|
Std. Mean Difference (Fixed, 95% CI) |
‐0.05 [‐0.46, 0.36] |
| 15.2 Tibolone 1.25 mg/day |
2 |
|
Std. Mean Difference (Fixed, 95% CI) |
‐0.62 [‐0.86, ‐0.38] |
| 15.3 Tibolone 2.5 mg/day |
4 |
|
Std. Mean Difference (Fixed, 95% CI) |
‐0.65 [‐0.80, ‐0.50] |
| 15.4 Tibolone 5 mg/day |
1 |
|
Std. Mean Difference (Fixed, 95% CI) |
‐0.84 [‐1.25, ‐0.43] |
